Noninvasive methods in evaluation of inflammatory bowel disease: Where do we stand now? An update

Clinics

Volumn 65, Issue 2, 2010, Pages 221-231

  Turkay, Cansel ^a   Kasapoglu, Benan ^a  

^a FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

Author keywords

Diagnosis; Fecal markers; Inflammatory bowel disease; Serology

Indexed keywords

BIOLOGICAL MARKER;

BLOOD; CHEMISTRY; ENTERITIS; FECES; HUMAN; REVIEW; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; SENSITIVITY AND SPECIFICITY;

EID: 77955728976     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322010000200015     Document Type: Review

References (74)

1. Wirtz,S, Neurath MF. Mouse models of inflammatory bowel disease, Adv. Drug Deliv. Rev. 2007;59:1073-83.
2. Hildebrand H, Finkel Y, Grahnquist L, Lindholm J, Ekbom A, Askling J. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001. Gut 2003;52:1432-34.
3. Baumgart DC. The Diagnosis and Treatment of Crohn's Disease and Ulcerative Colitis. Dtsch Arztebl Int. 2009;106:123-33.
4. Guindi M, Riddell RH. Indeterminate colitis. J. Clin. Pathol.2004;57:1233-44.
5. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133:1670-89.
6. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMNelastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162-9.
7. Van Limbergen J, Russell RK, Nimmo ER, Ho GT, Arnott ID, Wilson DC, et al. Genetics of the innate immune response in inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13:338-55.
8. Bruining DH, Loftus EV. Current and future diagnostic approaches: from serologies to imaging. Curr Gastroenterol Rep.2007;9:489-96.
9. Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease, World J. Gastroenterol.2008;14:5115-24.
10. Vermeire S, Vermeulen N, Van AG, Bossuyt X., and Rutgeerts P. (Auto)antibodies in inflammatory bowel diseases. Gastroenterol. Clin. North Am. 2008; 37:429-38.
11. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation, Annu. Rev. Immunol. 2002;20:495-549.
12. Papp M, Altorjay I, Norman GL, Shums Z, Palatka K, Vitalis Z, et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel. Dis. 2007;13,984-92.
13. Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort, Am J Gastroenterol. 2008;103,665-81.
14. Peyrin-Biroulet L, Standaert-Vitse A, Branche J, Chamaillard M. IBD serological panels: facts and perspectives. Inflamm Bowel Dis. 2007;13:1561-6.
15. Ferrante M, HenckaertsL, Joossens M, Pierik M, Joossens S, Dotan N, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56:1394-403.
16. Joossens M, Van Steen K, Branche J, Sendid B, Rutgeerts P, Vasseur F,et al. Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease. Inflamm Bowel Dis. 2009 Jun 5.
17. Mokrowiecka A, Daniel P, Słomka M, Majak P, Malecka-Panas E. Clinical utility of serological markers in inflammatory bowel disease. Hepatogastroenterology. 2009; 56:162-6.
18. Anand V, Russell AS, Tsuyuki R, Fedorak R. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis. Can J Gastroenterol. 2008;22:33-6.
19. Russell RK, Ip B, Aldhous MC, MacDougall M, Drummond HE, Arnott ID, et al. Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease.J Pediatr Gastroenterol Nutr. 2009;48:161-7.
20. Seow CH, Stempak JM, Xu W, Lan H, Griffiths AM, Greenberg GR, et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol. 2009;104:1426-34.
21. Chen CS, Sullivan S, Anderson T, Tan AC, Alex PJ, Brant SR, Cuffari C, et al. Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip. Mol Cell Proteomics. 2009;8:1765-76.
22. Hisabe T, Matsui T, Sakurai T, Murakami Y, Tanabe H, Matake H, et al. Anti- Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical value. J Gastroenterol. 2003;38:121-6.
23. Lawrance IC, Murray K, Hall A, Sung JJ, Leong R. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol 2004; 99: 2186-94.
24. Osada T, Ohkusa T, Okayasu I, Yoshida T, Hirai S, Beppu K, et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol. 2008;23 Suppl 2:S262-7.
25. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707-12.
26. Ha JS, Lee JS, Kim HJ, Moon TG, Chang DK, Lee JH, et al. Comparative usefulness of erythrocyte sedimentation rate and C-reactive protein in assessing the severity of ulcerative colitis.Korean J Gastroenterol. 2006;48:313-20.
27. Szkaradkiewicz A, Marciniak R, Chudzicka-Strugała I, Wasilewska A, Drews M, Majewski P, et al. Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp (Warsz). 2009;57:291-4.
28. Poullis A, Foster R, Northfield TC, Mendall MA. Review article: faecal markers in the assessment of activity in inflammatory bowel disease.Aliment Pharmacol Ther 2002;16:675-81.
29. Saverymuttu SH, Peters AM, Lavender JP, Pepys MB, Hodgson HJ, Chadwick SV. Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease.Gastroenterology. 1983;85:1333-9.
30. Karbach U, Ewe K, Bodenstein H. Alpha 1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn's disease. Gut 1983;24:718-23.
31. Becker K, Berger M, Niederau C, Frieling T. Individual fecal alpha 1- antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis. Hepatogastroenterology. 1999;46:2309-14.
32. Becker K, Niederau C, Frieling T. Fecal excretion of alpha 2 macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease. Z Gastroenterol 1999;37:597-605.
33. Crama-Bohbouth GEBI, Pena AS. Significance of faecal lysozme excretion and alph-1-antitrypsin clearance in the assessment of activity of inflammatory bowel disease. In: Ge B, editor. Activity Related Abnormalities in Inflammatory Bowel Disease. Woerden-Huybregts Press; 1998. p. 89-103.
34. Silberer H, Küppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 2005;51:117-26.
35. Langhorst J, Elsenbruch S, Mueller T, Rueffer A, Spahn G, Michalsen A, et al. Comparison of 4 neutrophilderive proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis. 2005;11:1085-91.
36. Saiki T. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Kurume Med J. 1998;45:69-73.
37. Dwarakanath AD, Finnie IA, Beesley CM, O'Dowd GM, Nash J, Tsai HH, et al. Differential excretion of leucocyte granule components in inflammatory bowel disease: implications for pathogenesis. Clin Sci. 1997;92:307-13.
38. Adeyemi EO, Hodgson HJ. Faecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol. 1992;27:139-42.
39. Sugi KSO, Hiarata I, Katsu K. Faecal lactoferrin as a marker of disease activity in inflammatory bowel disease: comparison with other neutrophil derived proteins. Am J Gastroenterol 1996;91:927-34.
40. Guerrant RL, Araujo V, Soares E, Kotloff K, Lima AA, Cooper WH, et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol. 1992;30:1238-42.
41. Angriman I, Scarpa M, D'Incà R, Basso D, Ruffolo C, Polese L, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007;381:63-8.
42. Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1440-4.
43. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.Am J Gastroenterol. 2003;98:1309-14.
44. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14:32-9.
45. Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum. 2007;50:1697-706.
46. Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 1990;336:763-5.
47. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793-8.
48. Erbayrak M, Turkay C, Eraslan E, Cetinkaya H, Kasapoglu B, Bektas M. The role of fecal calprotectin in investigating inflammatory bowel diseases. Clinics. 2009;64:421-5.
49. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009 May 21.
50. Eder P, Stawczyk-Eder K, Krela-Kaźmierczak I, Linke K. Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease. Pol Arch Med Wewn. 2008;118:622-6.
51. Gisbert JP, Bermejo F, Pérez-Calle JL, Taxonera C, Vera I, McNicholl AG, et al. Inflamm Bowel Dis. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.2009;15:1190-8.
52. D'Incà R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, et al. Can calprotectin predict relapse risk in inflammatory bowel disease?Am J Gastroenterol. 2008;103:2007-14.
53. Fagerberg UL, Lööf L, Merzoug RD, Hansson LO, Finkel Y. Fecal calprotectin levels in healthy children studied with an improved assay.J Pediatr Gastroenterol Nutr. 2003;37:468-72.
54. Montalto M, Curigliano V, Santoro L, Lombardi M, Covino M, Cammarota G, et al. Prophylactic aspirin therapy does not increase faecal calprotectin concentrations.Eur J Gastroenterol Hepatol. 2006;18:965-7.
55. Shiotani A, Kamada T, Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future.J Gastroenterol. 2008;43:581-8.
56. Røseth AG, Kristinsson J, Fagerhol MK, Schjønsby H, Aadland E, Nygaard K, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol. 1993;28:1073-6.
57. Husebye E, Tøn H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol. 2001;96:2683-7.
58. Czub E, Herzig KH, Szaflarska-Popawska A, Kiehne K, Socha P, Woś H, et al. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease.Scand J Gastroenterol. 2007;42:1147-50.
59. Jeffery J, Lewis SJ, Ayling RM. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders. Inflamm Bowel Dis. 2009 May 21.
60. Lundberg JO, Hellström PM, Fagerhol MK, Weitzberg E, Røseth AG. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Gastroenterol Hepatol. 2005;2:96-102.
61. Reinders CI, Herulf M, Ljung T, Hollenberg J, Weitzberg E, Lundberg JO,et al. Rectal mucosal nitric oxide in differentiation of inflammatory bowel disease and bowel syndrome.Clin Gastroenterol Hepatol. 2005:3:777-83.
62. Reinders CA, Jonkers D, Janson EA, Stockbrügger RW, Stobberingh EE, Hellström PM, et al. Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1151-7.
63. Ljung T, Lundberg S, Varsanyi M, Johansson C, Schmidt PT, Herulf M, et al. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders.World J Gastroenterol. 2006;12:3386-92.
64. Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97:1755-62.
65. Peterson CG, Sangfelt P, Wagner M, Hansson T, Lettesjö H, Carlson M. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest. 2007;67:810-20.
66. Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease.World J Gastroenterol. 2008;14:5584-9.
67. Bischoff SC, Wedemeyer J, Herrmann A, Meier PN, Trautwein C, Cetin Y, et al. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology. 1996;28:1-13.
68. Lamb CA, Mohiuddin MK, Gicquel J, Neely D, Bergin FG, Hanson JM, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease.Br J Surg. 2009;96:663-74.
69. Ashorn S, Honkanen T, Kolho KL, Ashorn M, Välineva T, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:199-205.
70. Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:669-73.
71. Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis.World J Gastroenterol. 2008;7;14:53-7.
72. Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104:673-8.
73. Sipponen T, Kärkkäinen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221-9.
74. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162-9.